| Literature DB >> 26631873 |
Carrie C Lubitz1, Sareh Parangi2, Tammy M Holm2, M Jordana Bernasconi2, Aislyn P Schalck3, Hyunsuk Suh2, Konstantinos P Economopoulos4, Viswanath Gunda2, Samuel E Donovan3, Peter M Sadow5, Lori J Wirth3, Ryan J Sullivan3, David J Panka6.
Abstract
BRAF(V600E) is a common mutation in papillary thyroid carcinoma (PTC) correlated with aggressive features. Our objective was to assess the feasibility and accuracy of a novel RNA-based blood assay to identify individuals with a high-risk tumor mutation in patients with PTC. Patients with benign or malignant thyroid disorders were included between September 2013 and July 2014 before either thyroidectomy (n = 62) or treatment of recurrent or metastatic PTC (n = 8). RNA was isolated from peripheral blood lymphocytes and reverse transcribed and followed by two rounds of nested PCR amplification with a restriction digest specific for wild-type BRAF. BRAF(V600E) levels were quantified with standardization curves. Circulating BRAF(V600E) levels were compared with BRAF mutation status from surgical pathologic DNA-based tissue assays. Testing characteristics and receiving-operator curve using tissue results as the gold standard were assessed. Matched blood and tissue assays for BRAF(V600E) were performed on 70 patients with PTC (stages I to IV, n = 48) or other (n = 22) thyroid tumors. Sixty-three percent of PTC patients tested positive for BRAF(V600E) with conventional tissue assays on surgical specimens. The correlation between the RNA-based blood assay and tissue BRAF status was 0.71. PTC patients harbor detectable BRAF(V600E) circulating tumor cells. This blood assay is feasible and has potential as a biomarker for prognosis, surveillance, clinical decision making, and assessment of treatment response to BRAF-targeted therapies.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26631873 PMCID： PMC4715220 DOI： 10.1016/j.jmoldx.2015.08.003
Source DB: PubMed Journal: J Mol Diagn ISSN： 1525-1578 Impact factor: 5.568